Development of a potent 2-oxoamide inhibitor of secreted phospholipase A2 guided by molecular docking calculations and molecular dynamics simulations

Publication date: Available online 2 March 2016
Source:Bioorganic & Medicinal Chemistry
Author(s): Sofia Vasilakaki, Efrosini Barbayianni, Georgios Leonis, Manthos G. Papadopoulos, Thomas Mavromoustakos, Michael H. Gelb, George Kokotos
Inhibition of group IIA secreted phospholipase A2 (GIIA sPLA2) has been an important objective for medicinal chemists. We have previously shown that inhibitors incorporating the 2-oxoamide functionality may inhibit human and mouse GIIA sPLA2s. Herein, the development of new potent inhibitors by molecular docking calculations using the structure of the known inhibitor 7 as scaffold, are described. Synthesis and biological evaluation of the new compounds revealed that the long chain 2-oxoamide based on (S)-valine GK241 led to improved activity (IC50 = 143 nM and 68 nM against human and mouse GIIA sPLA2, respectively). In addition, molecular dynamics simulations were employed to shed light on GK241 potent and selective inhibitory activity.

Graphical abstract

from #Medicine via ola Kala on Inoreader http://ift.tt/1TS2det
via IFTTT